Marshall Wace’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Marshall Wace's ACAD Position: Q3 2026 in Review
Marshall Wace reduced its Acadia Pharmaceuticals (ACAD) stake by 55% in Q3 2026, selling an estimated $26.1M and leaving 794,317 shares worth $16M. The position accounts for 0.01% of the portfolio, ranked #776.
Marshall Wace first reported a position in ACAD in Q1 2015 and has held it in 19 quarters since. The position peaked at $50.3M in Q3 2025. 346 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Marshall Wace held 794,317 shares of Acadia Pharmaceuticals worth $16M as of Q3 2026.
- Marshall Wace sold 970,521 Acadia Pharmaceuticals shares in Q3 2026, an estimated $26.1M.
- Acadia Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q3 2026, its #776 holding.
- Marshall Wace first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 19 quarters since.
- Marshall Wace's Acadia Pharmaceuticals position peaked at $50.3M in Q3 2025.
- 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.